In mice, eating lots of soybean oil makes them fatter, more insulin resistant, and gives them fatty livers—worse than eating coconut oil—even when they eat the same number of calories and fat.
Scientific Claim
Animal studies suggest that diets high in RBD soy oil promote greater insulin resistance, weight gain, and fatty liver compared to diets high in saturated fats from coconut oil, even when total fat and calorie intake are matched.
Original Statement
“Sladek et al. showed that an RBD oil diet promotes more visceral and ectopic fat formation than coconut oil... mice fed a diet similar in its total PUFA content to that of the average US consumer exhibited greater insulin resistance, weight gain, adiposity, and fatty liver compared to those fed a diet high in saturated fats from coconut oil.”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
probability
Can suggest probability/likelihood
Assessment Explanation
The claim is based on controlled animal studies, which can show comparative effects but not human causation. The study correctly frames it as an animal finding, though it implies human relevance.
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Randomized Controlled TrialLevel 1bWhether RBD soy oil causes greater insulin resistance than coconut oil in humans under controlled conditions.
Whether RBD soy oil causes greater insulin resistance than coconut oil in humans under controlled conditions.
What This Would Prove
Whether RBD soy oil causes greater insulin resistance than coconut oil in humans under controlled conditions.
Ideal Study Design
A 16-week double-blind RCT of 80 overweight adults randomized to consume 30% of calories from RBD soy oil vs. coconut oil, with isocaloric intake, measuring HOMA-IR, liver fat via MRI, and adipose tissue inflammation via biopsy.
Limitation: Ethical and practical constraints limit long-term high-fat diets in humans.
Controlled Animal StudyLevel 4In EvidenceWhether the metabolic effects of RBD soy oil are reproducible across strains and diets.
Whether the metabolic effects of RBD soy oil are reproducible across strains and diets.
What This Would Prove
Whether the metabolic effects of RBD soy oil are reproducible across strains and diets.
Ideal Study Design
A multi-center replication study in 3 labs using C57BL/6, DBA/2, and FVB mice fed isocaloric diets with 30% fat from RBD soy oil vs. coconut oil, measuring insulin sensitivity, liver histology, and adipokine profiles over 24 weeks.
Limitation: Cannot be generalized to humans without human trials.
Prospective Cohort StudyLevel 2bWhether higher RBD soy oil intake predicts incident insulin resistance or NAFLD in humans.
Whether higher RBD soy oil intake predicts incident insulin resistance or NAFLD in humans.
What This Would Prove
Whether higher RBD soy oil intake predicts incident insulin resistance or NAFLD in humans.
Ideal Study Design
A 10-year prospective cohort of 10,000 U.S. adults with dietary intake quantified via food frequency and biomarkers, measuring incident T2DM and NAFLD via liver enzymes and ultrasound.
Limitation: Cannot isolate soy oil from other dietary or lifestyle factors.
Evidence from Studies
Supporting (1)
This study says that processed soy oil messes up your body’s ability to use sugar properly, leading to weight gain and liver problems—exactly what the claim says. It doesn’t directly compare it to coconut oil, but it still shows soy oil is bad for metabolism.